Compare Gilead Sciences, Inc. (GILD) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United Microelectronics Corp — how do they compare? Gilead Sciences, Inc. trades at $136.67 (market cap $168.35B), while United Microelectronics Corp trades at $19.48 (market cap $47.81B). The key difference: Gilead Sciences, Inc. is far larger — about 3.5× United Microelectronics Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | UMC | |
|---|---|---|
Market Cap | $168.35B | $47.81B |
Sector | Health | Technology |
52-Week High | $155.80 | $28.02 |
52-Week Low | $110.56 | $6.58 |
Enterprise Value | $191.42B | $44.93B |
Dividend Yield | 2.42% | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
UMC trades at $18.79, up 0.37% today, with a bearish technical signal. Recent earnings beats and strong July 2026 sales growth of 18.98% year-over-year highlight operational momentum. The company is expanding capacity in Singapore and Taiwan to meet AI-driven demand, supported by a robust balance sheet with $115.24 billion in cash. However, net income margin has declined from 32.1% in 2022 to 16.99% in 2025, posing a concern.
The outlook is mixed; expansion initiatives and AI tailwinds offer growth potential, but margin compression and a bearish technical stance present risks. Analyst consensus is cautious with 53.33% hold ratings. Key catalysts include Q3 2026 earnings and fab expansion progress, while competitive pressures and macroeconomic volatility remain headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
